In Infergen trials, the maximum overdose reported was a dose of 150 mcg Infergen administered SC in a patient enrolled in a phase 1 advanced malignancy trial. The patient received 10 times the prescribed dosage for 3 days. The patient experienced a mild increase in anorexia, chills, fever, and myalgia. Increases in ALT (15 to 127 IU/L), aspartate transaminase (AST) (15 to 164 IU/L), and lactic dehydrogenase (LDH) (183 to 281 IU/L) were reported. These laboratory values returned to normal or to the patient's baseline values within 30 days.

Infergen is contraindicated in patients with known hypersensitivity to alpha interferons, to E coli-derived products, or to any component of the product.

Bookmark this page: